Shares of Allogene Therapeutics (NASDAQ:ALLO) rallied 22% in early afternoon trading Friday in the wake of its Q3 earnings report and two presentations at a medical meeting in San Diego.
Late Thursday, Allogene reported a narrower-than-expected Q3 loss, with $497.7M in cash and equivalents as of Sept. 30. The company’s cash runway is expected to run into 2H 2025.
On Friday, Allogene presented preclinical data for its Cloak and Dagger Technologies and product candidate ALLO-182 for the treatment of Claudin 18.2-positive gastric and pancreatic cancer tumors. The presentations were made at a meeting of the Society for Immunotherapy of Cancer in San Diego.
Allogene shares rally 22% amid Q3 report, medical meeting presentations
